202 related articles for article (PubMed ID: 30912959)
1. Multiparametric MRI-guided dose boost to dominant intraprostatic lesions in CT-based High-dose-rate prostate brachytherapy.
Wang T; Press RH; Giles M; Jani AB; Rossi P; Lei Y; Curran WJ; Patel P; Liu T; Yang X
Br J Radiol; 2019 May; 92(1097):20190089. PubMed ID: 30912959
[TBL] [Abstract][Full Text] [Related]
2. A planning study of focal dose escalations to multiparametric MRI-defined dominant intraprostatic lesions in prostate proton radiation therapy.
Wang T; Zhou J; Tian S; Wang Y; Patel P; Jani AB; Langen KM; Curran WJ; Liu T; Yang X
Br J Radiol; 2020 Mar; 93(1107):20190845. PubMed ID: 31904261
[TBL] [Abstract][Full Text] [Related]
3. Dosimetric evaluation of MRI-to-ultrasound automated image registration algorithms for prostate brachytherapy.
Shaaer A; Paudel M; Davidson M; Semple M; Nicolae A; Mendez LC; Chung H; Loblaw A; Tseng CL; Morton G; Ravi A
Brachytherapy; 2020; 19(5):599-606. PubMed ID: 32712028
[TBL] [Abstract][Full Text] [Related]
4. Inverse planning for HDR prostate brachytherapy used to boost dominant intraprostatic lesions defined by magnetic resonance spectroscopy imaging.
Pouliot J; Kim Y; Lessard E; Hsu IC; Vigneron DB; Kurhanewicz J
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):1196-207. PubMed ID: 15234056
[TBL] [Abstract][Full Text] [Related]
5. Dose to the dominant intraprostatic lesion using HDR vs. LDR monotherapy: A Phase II randomized trial.
Tissaverasinghe S; Crook J; Bachand F; Batchelar D; Hilts M; Araujo C; Anderson D; Bainbridge T; Farnquist B
Brachytherapy; 2019; 18(3):299-305. PubMed ID: 30795889
[TBL] [Abstract][Full Text] [Related]
6. Prostate stereotactic ablative radiation therapy using volumetric modulated arc therapy to dominant intraprostatic lesions.
Murray LJ; Lilley J; Thompson CM; Cosgrove V; Mason J; Sykes J; Franks K; Sebag-Montefiore D; Henry AM
Int J Radiat Oncol Biol Phys; 2014 Jun; 89(2):406-15. PubMed ID: 24685447
[TBL] [Abstract][Full Text] [Related]
7. IMRT boost dose planning on dominant intraprostatic lesions: gold marker-based three-dimensional fusion of CT with dynamic contrast-enhanced and 1H-spectroscopic MRI.
van Lin EN; Fütterer JJ; Heijmink SW; van der Vight LP; Hoffmann AL; van Kollenburg P; Huisman HJ; Scheenen TW; Witjes JA; Leer JW; Barentsz JO; Visser AG
Int J Radiat Oncol Biol Phys; 2006 May; 65(1):291-303. PubMed ID: 16618584
[TBL] [Abstract][Full Text] [Related]
8. Effect on therapeutic ratio of planning a boosted radiotherapy dose to the dominant intraprostatic tumour lesion within the prostate based on multifunctional MR parameters.
Riches SF; Payne GS; Desouza NM; Dearnaley D; Morgan VA; Morgan SC; Partridge M
Br J Radiol; 2014 May; 87(1037):20130813. PubMed ID: 24601648
[TBL] [Abstract][Full Text] [Related]
9. Image-guided high-dose-rate brachytherapy boost to the dominant intraprostatic lesion using multiparametric magnetic resonance imaging including spectroscopy: Results of a prospective study.
Vigneault E; Mbodji K; Racine LG; Chevrette E; Lavallée MC; Martin AG; Després P; Beaulieu L
Brachytherapy; 2016; 15(6):746-751. PubMed ID: 27743955
[TBL] [Abstract][Full Text] [Related]
10. Clinical evaluation of an MRI-to-ultrasound deformable image registration algorithm for prostate brachytherapy.
Shaaer A; Davidson M; Semple M; Nicolae A; Mendez LC; Chung H; Loblaw A; Tseng CL; Morton G; Ravi A
Brachytherapy; 2019; 18(1):95-102. PubMed ID: 30287271
[TBL] [Abstract][Full Text] [Related]
11. Feasibility of dominant intraprostatic lesion boosting using advanced photon-, proton- or brachytherapy.
Andrzejewski P; Kuess P; Knäusl B; Pinker K; Georg P; Knoth J; Berger D; Kirisits C; Goldner G; Helbich T; Pötter R; Georg D
Radiother Oncol; 2015 Dec; 117(3):509-14. PubMed ID: 26349588
[TBL] [Abstract][Full Text] [Related]
12. Ultrasound-planned high-dose-rate prostate brachytherapy: dose painting to the dominant intraprostatic lesion.
Crook J; Ots A; Gaztañaga M; Schmid M; Araujo C; Hilts M; Batchelar D; Parker B; Bachand F; Milette MP
Brachytherapy; 2014; 13(5):433-41. PubMed ID: 24958556
[TBL] [Abstract][Full Text] [Related]
13. Dominant intraprostatic lesion boosting in sexual-sparing radiotherapy of prostate cancer: A planning feasibility study.
Ciabatti S; Ntreta M; Buwenge M; Gaudiano C; Sessagesimi E; Romani F; Angelini AL; Cammelli S; Macchia G; Deodato F; Zamagni A; Golfieri R; Morganti AG; Cilla S
Med Dosim; 2019 Winter; 44(4):356-364. PubMed ID: 30955990
[TBL] [Abstract][Full Text] [Related]
14. Dosimetric feasibility of ablative dose escalated focal monotherapy with MRI-guided high-dose-rate (HDR) brachytherapy for prostate cancer.
Hosni A; Carlone M; Rink A; Ménard C; Chung P; Berlin A
Radiother Oncol; 2017 Jan; 122(1):103-108. PubMed ID: 27916416
[TBL] [Abstract][Full Text] [Related]
15. Multi-parametric MRI-guided focal tumor boost using HDR prostate brachytherapy: a feasibility study.
Mason J; Al-Qaisieh B; Bownes P; Wilson D; Buckley DL; Thwaites D; Carey B; Henry A
Brachytherapy; 2014; 13(2):137-45. PubMed ID: 24268487
[TBL] [Abstract][Full Text] [Related]
16. Effect of androgen deprivation therapy on intraprostatic tumour volume identified on
Chan J; Carver A; Brunt JN; Vinjamuri S; Syndikus I
Br J Radiol; 2017 Mar; 90(1071):20160818. PubMed ID: 27993093
[TBL] [Abstract][Full Text] [Related]
17. Prostate CT segmentation method based on nonrigid registration in ultrasound-guided CT-based HDR prostate brachytherapy.
Yang X; Rossi P; Ogunleye T; Marcus DM; Jani AB; Mao H; Curran WJ; Liu T
Med Phys; 2014 Nov; 41(11):111915. PubMed ID: 25370648
[TBL] [Abstract][Full Text] [Related]
18. Improved prostate delineation in prostate HDR brachytherapy with TRUS-CT deformable registration technology: A pilot study with MRI validation.
Yang X; Rossi PJ; Jani AB; Mao H; Zhou Z; Curran WJ; Liu T
J Appl Clin Med Phys; 2017 Jan; 18(1):202-210. PubMed ID: 28291925
[TBL] [Abstract][Full Text] [Related]
19. Open MR-guided high-dose-rate (HDR) prostate brachytherapy: feasibility and initial experiences open MR-guided high-dose-rate (HDR) prostate brachytherapy.
Lakosi F; Antal G; Vandulek C; Kovacs A; Toller GL; Rakasz I; Bajzik G; Hadjiev J; Bogner P; Repa I
Pathol Oncol Res; 2011 Jun; 17(2):315-24. PubMed ID: 21221879
[TBL] [Abstract][Full Text] [Related]
20. MRS-guided HDR brachytherapy boost to the dominant intraprostatic lesion in high risk localised prostate cancer.
Kazi A; Godwin G; Simpson J; Sasso G
BMC Cancer; 2010 Sep; 10():472. PubMed ID: 20809986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
